Revenue by quarter
US$ · last 8| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4.3B | $1.3B | 12.23 |
| Q1 FY2026 | $3.6B | $727.2M | 6.75 |
| Q4 FY2025 | $3.9B | $844.6M | 7.86 |
| Q3 FY2025 | $3.8B | $1.5B | 13.62 |
Newest filings
All 639| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 8-K | 6 Oct 2026 | 6 Oct, 7:51 AM | |
| 8-K | 30 Sep 2026 | 30 Sep, 4:14 PM | |
| N-PX | 20 Aug 2026 | ||
| 10-Q | 30 Jul 2026 | ||
| 8-K | 30 Jul 2026 | ||
| 8-K | 6 Jul 2026 | ||
| 8-K | 17 Jun 2026 | ||
| 10-Q | 29 Apr 2026 |
Description
- Ticker
- REGN-US
- Exchange
- Nasdaq
- Index
- S&P 500
- Industry
- Pharmaceutical Preparations
- SIC division
- Manufacturing
- CIK
- 0000872589
- LEI
- 549300RCBFWIRX3HYQ56
- FIGI
- BBG000C734W3
- Share class FIGI
- BBG001S6PX49
- Fiscal year ends
- Dec
- Filings held
- 639 since 1996
- 8-K events
- 280
- Shares short
- 2.2M, 30 Sep 2026
Financial statements
The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.
| Fiscal period | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Filed | 17 Feb 2011 | 21 Feb 2012 | 15 Feb 2013 | 13 Feb 2014 | 12 Feb 2015 | 11 Feb 2016 | 9 Feb 2017 | 8 Feb 2018 | 7 Feb 2019 | 7 Feb 2020 | 8 Feb 2021 | 7 Feb 2022 | 6 Feb 2023 | 5 Feb 2024 | 5 Feb 2025 | 4 Feb 2026 | 4 Feb 2026 | 4 Feb 2026 |
| +Revenue from contract with customer | – | – | – | – | – | – | – | – | 4,860M | 5,872M | 5,146Mr | 6,558Mr | 8,497M | 16,072M | 12,173M | 13,117M | 14,202M | 14,343M |
| +Research and development | 275M | 399M | 489M | 530M | 626M | 860M | 1,271M | 1,621M | 2,052Mr | 2,075Mr | 1,469Mr | 2,450Mr | 2,647Mr | 2,860Mr | 3,593M | 4,439M | 5,132M | 5,850M |
| +Acquired in-process research and development | – | – | – | – | – | – | – | – | – | – | – | – | 88M | 48M | 255M | 186M | 101M | 124M |
| +Selling, general, and administrative | 49M | 53M | 65M | 117M | 211M | 346Mr | 519Mr | 839M | 1,178Mr | 1,320Mr | 1,127Mr | 1,342Mr | 1,346M | 1,825M | 2,116M | 2,631M | 2,954M | 2,700M |
| +Cost of goods sold and of collaboration and contract manufacturing | – | – | – | – | – | – | – | – | – | – | 238M | 403M | – | – | – | – | – | – |
| −Other operating expense, net | – | – | – | – | – | – | – | – | – | – | 402M | 209M | 280M | 46M | 90M | 2.1M | -53M | 10M |
| −Total expenses | 325M | 453M | 557M | 651M | 921M | 1,362Mr | 1,996Mr | 2,852M | 3,530Mr | 3,793Mr | 2,611Mr | 4,348Mr | 4,921M | 7,125M | 7,434M | 9,070M | 10,211M | 10,765M |
| Income from operations | -86M | -74M | -98M | -205M | 458M | 743Mr | 824Mr | 1,252M | 1,331Mr | 2,080Mr | 2,534M | 2,210M | 3,577M | 8,947M | 4,739M | 4,047M | 3,991M | 3,578M |
| % of total revenues | -36.2% | -19.5% | -21.2% | -46.0% | 33.2% | 35.3% | 29.2% | 30.5% | 27.4% | 35.4% | ||||||||
| +Other income, net | – | – | – | – | – | -0.2M | -25Mr | -13Mr | 6.3Mr | 24Mr | 47M | 250M | 291M | 436M | 179M | 225M | 844M | 1,697M |
| −Interest expense | 7.8M | 2.3M | 9.1M | 21M | 45M | 46M | 37M | 14M | 7.2M | 25M | 28M | 30M | 57M | 57M | 59M | 73M | 55M | 44M |
| Total other income | 9.5M | 2.2M | -7M | -18M | -43M | -47M | -63M | -27M | -0.9Mr | -1.1Mr | 19M | 219M | 234M | 379M | 120M | 152M | 789M | 1,653M |
| Income before income taxes | -77M | -72M | -105M | -223M | 414M | 696Mr | 761Mr | 1,225M | 1,330Mr | 2,079Mr | 2,554M | 2,429M | 3,810M | 9,326M | 4,859M | 4,199M | 4,780M | 5,231M |
| % of total revenues | -32.2% | -19.0% | -22.8% | -50.0% | 30.1% | 33.1% | 27.0% | 29.9% | 27.4% | 35.4% | ||||||||
| −Income tax expense | 2.4M | -4.1M | 0M | -1.1M | -336M | 283Mr | 423Mr | 589M | 434Mr | 880M | 109M | 313M | 297M | 1,251M | 520M | 246M | 367M | 726M |
| Net income | -79M | -68M | -105M | -222M | 750M | 414Mr | 338Mr | 636M | 896Mr | 1,199Mr | 2,444M | 2,116M | 3,513M | 8,075M | 4,338M | 3,954M | 4,413M | 4,505M |
| % of total revenues | -33.2% | -17.9% | -22.8% | -49.7% | 54.4% | 19.7% | 12.0% | 15.5% | 18.4% | 20.4% | ||||||||
| Net income per share - basic | – | – | -1.26 | -2.45 | 7.92 | 4.23 | 3.36 | 6.17 | 8.55 | 11.27 | 22.65 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 | 43.07 |
| Net income per share - diluted | – | – | -1.26 | -2.45 | 6.75 | 3.72 | 2.98 | 5.52 | 7.70 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| Weighted average shares outstanding - basic | – | – | 83M | 91M | 95M | 98M | 101M | 103M | 105Mr | 106Mr | 108M | 109M | 108M | 106M | 107M | 107M | 108M | 105M |
| Weighted average shares outstanding - diluted | – | – | 83M | 91M | 115M | 111M | 113M | 115M | 116Mr | 116Mr | 115M | 115M | 115M | 112M | 114M | 114M | 115M | 109M |
| +Unrealized gain on debt securities | – | – | -3.5M | 0.6M | 0.7M | -0M | 53M | -44M | -21Mr | 13Mr | -7M | 36M | 9.1M | -56M | -214M | 158M | 74M | 83M |
| +Gain on foreign currency translation | – | – | – | – | – | – | – | – | – | – | – | – | – | 0M | 0M | -0.3M | -0.6M | 2.4M |
| Unrealized gain on cash flow hedges | – | – | – | – | – | – | – | – | – | – | 0.7M | -2.5M | -0.9M | 0.9M | 1M | 0M | 0M | – |
| Comprehensive income | – | – | -108M | -221M | 751M | 414Mr | 392Mr | 592M | 874Mr | 1,212Mr | 2,438M | 2,149M | 3,521M | 8,020M | 4,126M | 4,112M | 4,486M | 4,590M |
Hover a figure for its source.r restated in a later filing– not reported in that period
Lines in the order and wording of the 10-K filed 4 Feb 2026. 286 of 287 subtotals add up to the company's own totals, and the balance sheet balances in 82 of 82 periods. Newest filing read: 30 Jul 2026.
Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.
Charts
Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.
Revenue · quarterly · US$
Latest Jun 2026: $4.29B
Revenue = rev
Method. Each month-end, the trailing-twelve-month diluted EPS known that month (from filings filed by then) at the 10th, 50th and 90th percentile of this stock's own month-end P/E from 2013-11 to 2026-10. Months with the figure at or below zero are left out. A summary of the multiples the stock has traded at, not a value.
Ratios
Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.
| Fiscal year ending | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on common equity | – | – | −22.6% | −43.8% | 86.1% | 25.7% | 15.0% | 20.5% | 22.1% | 22.6% | 32.8% | 21.3% | 31.8% | 54.2% | 20.9% | 16.3% | 16.0% | 14.9% |
| Return on assets | – | – | −11.4% | −18.4% | 44.1% | 16.4% | 10.0% | 13.5% | 14.2% | 15.2% | 23.8% | 15.9% | 22.0% | 37.9% | 15.9% | 12.7% | 12.5% | 11.5% |
| Return on capital | – | – | −21.1% | −40.3% | 41.5% | 27.4% | 16.2% | 20.9% | 21.8% | 22.4% | 31.1% | 18.7% | 27.4% | 45.9% | 18.6% | 14.5% | 12.4% | 9.5% |
| Return on invested capital | – | – | −58.4% | −172.1% | 79.7% | 39.8% | 25.0% | 30.5% | 29.2% | 29.0% | 42.6% | 26.5% | 38.1% | 63.3% | 26.5% | 22.4% | 18.7% | 13.1% |
| Gross margin | 99.6% | 99.6% | 99.5% | 99.1% | 93.9% | 94.4% | 95.4% | 94.1% | 96.0% | 96.6% | 95.4% | 93.9% | – | – | – | – | – | – |
| EBITDA margin | −31.4% | −15.8% | −16.9% | −39.0% | 35.9% | 37.3% | 31.1% | 32.3% | 29.5% | 37.9% | 52.1% | 36.9% | 44.9% | 57.4% | 41.7% | 34.1% | 31.5% | 28.7% |
| Operating margin | −36.2% | −19.5% | −21.2% | −46.0% | 33.2% | 35.3% | 29.2% | 30.5% | 27.4% | 35.4% | 49.3% | 33.7% | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% |
| Incremental operating margin | – | 8.6% | −29.3% | 812.7% | 71.1% | 39.3% | 11.3% | 33.3% | 10.4% | 74.0% | −62.6% | −23.0% | 70.5% | 70.9% | 107.9% | −73.3% | −5.2% | −293.0% |
| Pretax margin | −32.2% | −19.0% | −22.8% | −50.0% | 30.1% | 33.1% | 27.0% | 29.9% | 27.4% | 35.4% | 49.6% | 37.0% | 44.8% | 58.0% | 39.9% | 32.0% | 33.7% | 36.5% |
| Profit margin | −33.2% | −17.9% | −22.8% | −49.7% | 54.4% | 19.7% | 12.0% | 15.5% | 18.4% | 20.4% | 47.5% | 32.3% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| Net income to common margin | −33.2% | −17.9% | −22.8% | −49.7% | 54.4% | 19.7% | 12.0% | 15.5% | 18.4% | 20.4% | 47.5% | 32.3% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| Effective tax rate | −3.1% | 5.7% | 0.0% | 0.5% | −81.0% | 40.6% | 55.6% | 48.1% | 32.7% | 42.3% | 4.3% | 12.9% | 7.8% | 13.4% | 10.7% | 5.9% | 7.7% | 13.9% |
| Dividend payout ratio | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 8.2% |
| Sustainable growth rate | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 16.3% | 16.0% | 13.6% |
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
Key points
Revenue rose 17 percent
Total revenues were $4,291 million against $3,676 million. GAAP net income was $1,297 million, down 7%; non-GAAP net income was $1,543 million, up 8%.
Non-GAAP EPS rose 11 percent
Non-GAAP diluted EPS was $14.29 against $12.89. GAAP diluted EPS was $12.23 against $12.81. Both figures include IPR&D charges of $1.02 and $0.99 per share.
Sanofi collaboration revenue rose 51 percent
Sanofi collaboration revenue was $2,174 million against $1,444 million. Regeneron's share of antibody profits rose to $2.033 billion from $1.282 billion.
Profit share rose on Dupixent
The rise in profit share came mainly from higher profits tied to increased Dupixent sales, which Sanofi records and Regeneron shares through collaboration revenue.
Sanofi Development Balance fully repaid
The Sanofi Development Balance was fully repaid by the end of the second quarter. It will no longer reduce Sanofi collaboration revenue from the third quarter of 2026.
Bayer collaboration revenue declined
Bayer collaboration revenue was $276 million, down 33%. Regeneron's profit share on EYLEA 8 mg and EYLEA outside the United States was $227.3 million against $383.4 million.
Dupixent global sales rose 38 percent
Dupixent global net sales, recorded by Sanofi, reached a new all-time high of $6.0 billion. Regeneron records its share of profits in collaboration revenue.
EYLEA HD sales rose 52 percent
EYLEA HD U.S. net sales were $596 million. Higher volumes driven by increased demand were partly offset by a lower net selling price.
EYLEA U.S. sales fell 45 percent
EYLEA U.S. net sales were $412 million against $754 million. Total EYLEA HD and EYLEA U.S. sales were $1,008 million, down 12%.
Libtayo sales rose 30 percent
Global Libtayo net sales were $489 million. U.S. sales were $343 million, up 38%, and rest-of-world sales were $146 million, up 13%.
Praluent and Evkeeza sales rose
Praluent U.S. net sales were $75 million, up 14%. Evkeeza U.S. net sales were $53 million, up 29%.
Kevzara and other products
Kevzara global net sales were $206 million, up 35%. Other products were $85 million, up 17%. Lynozyfic global net sales were $17 million.
R&D spend rose on pipeline
GAAP R&D was $1,632 million, up 15%. Non-GAAP R&D was $1,500 million, up 17%. Management attributed the increase to the mid- and late-stage clinical pipeline.
Acquired IPR&D charge rose
Acquired IPR&D expense was $127 million against $10 million. It included up-front and opt-in payments under collaboration and licensing agreements.
Guidance
- GAAP R&D$6.500–$6.635 billionfull year 2026 · not stated from $6.450–$6.680 billion
- Non-GAAP R&D$5.950–$6.050 billionfull year 2026 · not stated from $5.900–$6.100 billion
- GAAP SG&A$2.830–$2.960 billionfull year 2026 · lowered from $2.860–$3.040 billion
- Non-GAAP SG&A$2.500–$2.600 billionfull year 2026 · lowered from $2.500–$2.650 billion
- GAAP gross margin on net product sales78%–79%full year 2026 · raised from 77%–78%
- Non-GAAP gross margin on net product sales84%–85%full year 2026 · raised from 83%–84%
- GAAP COCM$985 million–$1.035 billionfull year 2026 · not stated from $955 million–$1.035 billion
- Non-GAAP COCM$970 million–$1.020 billionfull year 2026 · not stated from $940 million–$1.020 billion
- Capital expenditures$1.030–$1.100 billionfull year 2026 · lowered from $1.100–$1.200 billion
- GAAP effective tax rate13%–14%full year 2026 · not stated from 12%–14%
- Non-GAAP effective tax rate14%–15%full year 2026 · not stated from 13%–15%
In their words
“With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases.” Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron
“Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures” Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron
“we continue to invest confidently in our pipeline, U.S. manufacturing, and external innovation, while returning capital to shareholders” Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron
Coming up
Collaboration profits to step up. Management expects a meaningful step-up in collaboration profits from the third quarter, once the Sanofi Development Balance no longer reduces revenue.
FDA target action date for cemdisiran. The FDA priority review of the cemdisiran NDA for gMG has a target action date in November 2026.
European decision on cemdisiran expected. A European Commission decision on cemdisiran for gMG is anticipated in the second half of 2027.
Dividend payable August 31. The $0.94 per share dividend is payable on August 31, 2026, to shareholders of record on August 18, 2026.
Conference call on July 30. Management will host a conference call and webcast on July 30, 2026, at 8:30 AM Eastern Time to discuss the quarter.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
This company reports no segment split in its annual report.
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 6 Oct 2026 | 6 Oct, 7:51 AM ET | 8-K | ResultsMaterial agreementOther events | 1.01, 2.02, 8.01 | |
| 30 Sep 2026 | 30 Sep, 4:14 PM ET | 8-K | Leadership change | 5.02, 9.01 | |
| 30 Jul 2026 | 8-K | Results | 2.02, 9.01 | ||
| 6 Jul 2026 | 8-K | Results | 2.02 | ||
| 17 Jun 2026 | 8-K | Shareholder vote | 5.07 | ||
| 29 Apr 2026 | 8-K | Results | 2.02, 9.01 | ||
| 8 Apr 2026 | 8-K | Results | 2.02 | ||
| 30 Jan 2026 | 8-K | Results | 2.02, 9.01 | ||
| 12 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 28 Oct 2025 | 8-K | Results | 2.02, 9.01 | ||
| 6 Oct 2025 | 8-K | Results | 2.02 | ||
| 1 Aug 2025 | 8-K | Results | 2.02, 9.01 | ||
| 18 Jun 2025 | 8-K | Shareholder vote | 5.07 | ||
| 29 Apr 2025 | 8-K | Results | 2.02, 9.01 | ||
| 4 Feb 2025 | 8-K | ResultsOther events | 2.02, 8.01, 9.01 | ||
| 13 Jan 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 31 Oct 2024 | 8-K | Results | 2.02, 9.01 | ||
| 7 Oct 2024 | 8-K | Results | 2.02 | ||
| 1 Aug 2024 | 8-K | Results | 2.02, 9.01 | ||
| 8 Jul 2024 | 8-K | Results | 2.02 | ||
| 20 Jun 2024 | 8-K | Shareholder vote | 5.07 | ||
| 2 May 2024 | 8-K | Results | 2.02, 9.01 | ||
| 2 Feb 2024 | 8-K | Results | 2.02, 9.01 | ||
| 31 Jan 2024 | 8-K | Leadership change | 5.02 | ||
| 8 Jan 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 2 Nov 2023 | 8-K | Results | 2.02, 9.01 | ||
| 5 Oct 2023 | 8-K | Results | 2.02 | ||
| 8 Sep 2023 | 8-K/A | Shareholder vote | 5.07 | ||
| 8 Sep 2023 | 8-K | Leadership change | 5.02 | ||
| 3 Aug 2023 | 8-K | Results | 2.02, 9.01 | ||
| 14 Jun 2023 | 8-K | Shareholder voteBylaws or fiscal year change | 5.03, 5.07, 9.01 | ||
| 4 May 2023 | 8-K | Results | 2.02, 9.01 | ||
| 17 Apr 2023 | 8-K | Leadership change | 5.02 | ||
| 10 Apr 2023 | 8-K | Results | 2.02 | ||
| 29 Mar 2023 | 8-K | Material agreementNew debt | 1.01, 2.03, 9.01 | ||
| 3 Feb 2023 | 8-K | Results | 2.02, 9.01 | ||
| 9 Jan 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 20 Dec 2022 | 8-K | Material agreementAgreement endedNew debt | 1.01, 1.02, 2.03, 9.01 | ||
| 3 Nov 2022 | 8-K | Results | 2.02, 9.01 | ||
| 3 Oct 2022 | 8-K | Leadership change | 5.02 | ||
| 3 Aug 2022 | 8-K | Results | 2.02, 9.01 | ||
| 15 Jun 2022 | 8-K | Shareholder vote | 5.07 | ||
| 2 Jun 2022 | 8-K | Material agreement | 1.01 | ||
| 4 May 2022 | 8-K | Results | 2.02, 9.01 | ||
| 8 Mar 2022 | 8-K | Material agreementNew debt | 1.01, 2.03, 9.01 | ||
| 4 Feb 2022 | 8-K | Results | 2.02, 9.01 | ||
| 10 Jan 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 4 Nov 2021 | 8-K | Results | 2.02, 9.01 | ||
| 16 Sep 2021 | 8-K | Material agreement | 1.01 | ||
| 5 Aug 2021 | 8-K | Results | 2.02, 9.01 |
Every filing
The company's filings with the SEC, newest first: 639 held. Insider, fund and large-holder filings have their own tables below.
| 6 Oct 2026 | 8-K | 1 Oct 2026 | 6 Oct, 7:51 AM ET | |
| 30 Sep 2026 | 8-K | 24 Sep 2026 | 30 Sep, 4:14 PM ET | |
| 20 Aug 2026 | N-PX | 30 Jun 2026 | ||
| 30 Jul 2026 | 10-Q | 30 Jun 2026 | ||
| 30 Jul 2026 | 8-K | 30 Jul 2026 | ||
| 6 Jul 2026 | 8-K | 6 Jul 2026 | ||
| 17 Jun 2026 | 8-K | 12 Jun 2026 | ||
| 29 Apr 2026 | 10-Q | 31 Mar 2026 | ||
| 29 Apr 2026 | 8-K | 29 Apr 2026 | ||
| 24 Apr 2026 | ARS | 31 Dec 2025 | ||
| 24 Apr 2026 | DEFA14A | – | ||
| 24 Apr 2026 | DEF 14A | 12 Jun 2026 | ||
| 8 Apr 2026 | 8-K | 8 Apr 2026 | ||
| 4 Feb 2026 | 10-K | 31 Dec 2025 | ||
| 30 Jan 2026 | 8-K | 30 Jan 2026 | ||
| 12 Jan 2026 | 8-K | 12 Jan 2026 | ||
| 28 Oct 2025 | 10-Q | 30 Sep 2025 | ||
| 28 Oct 2025 | 8-K | 28 Oct 2025 | ||
| 6 Oct 2025 | 8-K | 6 Oct 2025 | ||
| 1 Aug 2025 | 10-Q | 30 Jun 2025 | ||
| 1 Aug 2025 | 8-K | 1 Aug 2025 | ||
| 18 Jun 2025 | 8-K | 13 Jun 2025 | ||
| 29 Apr 2025 | 10-Q | 31 Mar 2025 | ||
| 29 Apr 2025 | 8-K | 29 Apr 2025 | ||
| 29 Apr 2025 | ARS | 31 Dec 2024 | ||
| 29 Apr 2025 | DEFA14A | – | ||
| 29 Apr 2025 | DEF 14A | 13 Jun 2025 | ||
| 17 Apr 2025 | UPLOAD | – | ||
| 7 Apr 2025 | PRE 14A | 13 Jun 2025 | ||
| 3 Apr 2025 | CORRESP | – | ||
| 21 Mar 2025 | UPLOAD | – | ||
| 5 Feb 2025 | 10-K | 31 Dec 2024 | ||
| 4 Feb 2025 | 8-K | 4 Feb 2025 | ||
| 13 Jan 2025 | 8-K | 13 Jan 2025 | ||
| 31 Oct 2024 | S-3ASR | – | ||
| 31 Oct 2024 | 10-Q | 30 Sep 2024 | ||
| 31 Oct 2024 | 8-K | 31 Oct 2024 | ||
| 7 Oct 2024 | 8-K | 7 Oct 2024 | ||
| 11 Sep 2024 | UPLOAD | – | ||
| 1 Aug 2024 | CORRESP | – | ||
| 1 Aug 2024 | 10-Q | 30 Jun 2024 | ||
| 1 Aug 2024 | 8-K | 1 Aug 2024 | ||
| 22 Jul 2024 | UPLOAD | – | ||
| 8 Jul 2024 | 8-K | 8 Jul 2024 | ||
| 20 Jun 2024 | 8-K | 14 Jun 2024 | ||
| 20 May 2024 | CORRESP | – | ||
| 9 May 2024 | UPLOAD | – | ||
| 2 May 2024 | 10-Q | 31 Mar 2024 | ||
| 2 May 2024 | 8-K | 2 May 2024 | ||
| 25 Apr 2024 | ARS | 31 Dec 2023 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 6 | $753.76 | $4.5K | 51,974 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 35 | $755.91 | $26.5K | 51,939 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 16 | $757.68 | $12.1K | 51,923 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 24 | $758.16 | $18.2K | 51,899 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 14 | $759.96 | $10.6K | 51,885 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 74 | $760.65 | $56.3K | 51,811 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 27 | $761.36 | $20.6K | 51,784 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 55 | $762.57 | $41.9K | 51,729 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 25 | $763.76 | $19.1K | 51,704 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 219 | $764.40 | $167.4K | 51,485 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 271 | $765.39 | $207.4K | 51,214 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 279 | $766.47 | $213.8K | 50,935 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 192 | $767.39 | $147.3K | 50,743 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 105 | $768.33 | $80.7K | 50,638 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 127 | $769.30 | $97.7K | 50,511 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 12 | $770.20 | $9.2K | 50,499 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 283 | $771.56 | $218.4K | 50,216 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 211 | $772.56 | $163.0K | 50,005 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 224 | $773.40 | $173.2K | 49,781 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 121 | $774.48 | $93.7K | 49,660 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 376 | $775.46 | $291.6K | 49,284 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 66 | $776.31 | $51.2K | 49,218 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 38 | $777.76 | $29.6K | 49,180 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 454 | $778.64 | $353.5K | 48,726 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 380 | $779.59 | $296.2K | 48,346 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 463 | $780.63 | $361.4K | 47,883 | 15 Oct 2026 |
| 14 Oct 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sale under a trading plan | 50 | $781.47 | $39.1K | 47,833 | 15 Oct 2026 |
| 3 Sep 2026 | Mccourt MarionEVP Commercial | Sale under a trading plan | 1,131 | $857.39 | $969.7K | 12,003 | 3 Sep 2026 |
| 2 Sep 2026 | Mccourt MarionEVP Commercial | Sale under a trading plan | 1,215 | $850.00 | $1.0M | 13,134 | 3 Sep 2026 |
| 2 Sep 2026 | Guarini KathrynDirector | Sale under a trading plan | 400 | $850.00 | $340.0K | 603 | 3 Sep 2026 |
| 10 Aug 2026 | Guarini KathrynDirector | Sale under a trading plan | 400 | $800.00 | $320.0K | 603 | 12 Aug 2026 |
| 10 Aug 2026 | Zoghbi Huda YDirector | Sale under a trading plan | 800 | $800.00 | $640.0K | 1,703 | 12 Aug 2026 |
| 2 Jul 2026 | Ryan Arthur FDirector | Sale under a trading plan | 200 | $650.15 | $130.0K | 17,303 | 7 Jul 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 5 | $701.76 | $3.5K | 17,598 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 15 | $702.46 | $10.5K | 17,583 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 24 | $703.46 | $16.9K | 17,559 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 15 | $704.28 | $10.6K | 17,544 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 14 | $705.56 | $9.9K | 17,530 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 7 | $706.74 | $4.9K | 17,523 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 4 | $707.40 | $2.8K | 17,519 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 6 | $709.45 | $4.3K | 17,513 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 2 | $710.87 | $1.4K | 17,511 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 5 | $711.49 | $3.6K | 17,506 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 1 | $712.09 | $712 | 17,505 | 4 May 2026 |
| 1 May 2026 | Ryan Arthur FDirector | Sale under a trading plan | 2 | $714.13 | $1.4K | 17,503 | 4 May 2026 |
| 1 Apr 2026 | Ryan Arthur FDirector | Sale under a trading plan | 1 | $771.32 | $771 | 17,702 | 3 Apr 2026 |
| 1 Apr 2026 | Ryan Arthur FDirector | Sale under a trading plan | 3 | $772.76 | $2.3K | 17,699 | 3 Apr 2026 |
| 1 Apr 2026 | Ryan Arthur FDirector | Sale under a trading plan | 8 | $773.59 | $6.2K | 17,691 | 3 Apr 2026 |
| 1 Apr 2026 | Ryan Arthur FDirector | Sale under a trading plan | 8 | $774.58 | $6.2K | 17,683 | 3 Apr 2026 |
| 1 Apr 2026 | Ryan Arthur FDirector | Sale under a trading plan | 14 | $775.58 | $10.9K | 17,669 | 3 Apr 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 14 Oct 2026 | MURPHY ANDREW JOfficer | 4,147 | $3.2M | 14 Oct 2026 |
| 3 Sep 2026 | McCourt MarionOfficer | 1,131 | $969.3K | 3 Sep 2026 |
| 2 Sep 2026 | Guarini KathrynDirector | 400 | $340.0K | 2 Sep 2026 |
| 2 Sep 2026 | McCourt MarionOfficer | 1,215 | $1.0M | 2 Sep 2026 |
| 10 Aug 2026 | Guarini KathrynBoard member | 400 | $320.0K | 10 Aug 2026 |
| 10 Aug 2026 | Zoghbi Huda YDirector | 800 | $640.0K | 10 Aug 2026 |
| 2 Jul 2026 | Arthur F. RyanDirector | 400 | $249.9K | 2 Jul 2026 |
| 19 Feb 2026 | Zoghbi Huda YDirector | 1,638 | $1.3M | 19 Feb 2026 |
| 9 Feb 2026 | Arthur F. RyanDirector | 400 | $314.2K | 9 Feb 2026 |
| 9 Feb 2026 | Pitofsky JasonOfficer | 2,036 | $1.6M | 9 Feb 2026 |
| 7 Jan 2026 | Bassler Bonnie LDirector | 1,500 | $1.2M | 7 Jan 2026 |
| 20 Nov 2025 | Bassler Bonnie LDirector | 760 | $570.0K | 20 Nov 2025 |
| 7 Nov 2025 | Jason PitofskyOfficer | 431 | $280.6K | 7 Nov 2025 |
| 29 Oct 2025 | Christine PoonDirector | 6,500 | $4.2M | 29 Oct 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 30 Apr 2026 | Vanguard Capital Management | 13G | 7.37% | 7.7M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
| 15 May 2026 | Gilbert CisnerosCA31 | Sale | $1,001 - $15,000 | Self | 8 Jun 2026 |
| 12 Feb 2026 | Julia LetlowLA05 | Purchase | $1,001 - $15,000 | Self | 12 Mar 2026 |
| 18 Nov 2025 | Gilbert CisnerosCA31 | Purchase | $1,001 - $15,000 | Self | 15 Dec 2025 |
| 15 May 2025 | Rob BresnahanPA08 | Purchase | $1,001 - $15,000 | Self | 9 Jun 2025 |
| 10 Apr 2025 | Byron DonaldsFL19 | Sale | $1,001 - $15,000 | Self | 24 May 2025 |
| 1 Apr 2025 | Julie JohnsonTX32 | Sale | $1,001 - $15,000 | JT | 14 May 2025 |
| 8 Apr 2025 | Rob BresnahanPA08 | Sale | $1,001 - $15,000 | Self | 8 May 2025 |
| 7 Apr 2025 | Jefferson ShreveIN06 | Sale | $15,001 - $50,000 | Self | 8 May 2025 |
| 25 Feb 2025 | Rob BresnahanPA08 | Sale | $1,001 - $15,000 | Self | 27 Mar 2025 |
| 12 Feb 2025 | Julie JohnsonTX32 | Sale (partial) | $1,001 - $15,000 | JT | 12 Mar 2025 |
| 15 Jan 2025 | Julie JohnsonTX32 | Purchase | $1,001 - $15,000 | JT | 12 Feb 2025 |
| 24 Jan 2025 | Josh GottheimerNJ05 | Sale | $1,001 - $15,000 | JT | 10 Feb 2025 |
| 13 Nov 2024 | Jonathan JacksonIL01 | Sale | $15,001 - $50,000 | JT | 12 Dec 2024 |
| 1 Nov 2024 | Jonathan JacksonIL01 | Sale (partial) | $1,001 - $15,000 | JT | 12 Dec 2024 |
| 29 Nov 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 5 Dec 2024 |
| 19 Nov 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 5 Dec 2024 |
| 15 Oct 2024 | Greg LandsmanOH01 | Sale | $1,001 - $15,000 | SP | 14 Nov 2024 |
| 23 Oct 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 6 Nov 2024 |
| 1 Jul 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 15 Aug 2024 |
| 11 Aug 2023 | Greg LandsmanOH01 | Purchase | $1,001 - $15,000 | SP | 14 Aug 2024 |
| 8 Feb 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 7 Mar 2024 |
| 17 Jan 2024 | Jonathan JacksonIL01 | Purchase | $1,001 - $15,000 | JT | 15 Feb 2024 |
| 13 Nov 2023 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 8 Dec 2023 |
| 21 Aug 2023 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 16 Sep 2023 |
| 11 Jul 2023 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 21 Aug 2023 |
| 22 Jun 2023 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 11 Jul 2023 |
| 23 Jun 2023 | Jonathan JacksonIL01 | Purchase | $15,001 - $50,000 | JT | 7 Jul 2023 |
| 6 Mar 2023 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 20 Apr 2023 |
| 21 Aug 2019 | Thomas SuozziNY03 | Sale (partial) | $1,001 - $15,000 | Self | 19 Dec 2022 |
| 19 Oct 2022 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 10 Nov 2022 |
| 12 Sep 2022 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 16 Oct 2022 |
| 1 Jul 2021 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 9 Aug 2021 |
| 21 Jul 2021 | Donald Sternoff Honorable BeyerVA08 | Purchase | $1,001 - $15,000 | JT | 7 Aug 2021 |
| 17 May 2021 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 15 Jun 2021 |
| 11 Jan 2021 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 9 Feb 2021 |
| 22 Dec 2020 | Gilbert CisnerosCA39 | Purchase | $1,001 - $15,000 | Self | 11 Jan 2021 |
| 11 Dec 2020 | Josh GottheimerNJ05 | Sale | $1,001 - $15,000 | JT | 7 Jan 2021 |
| 27 May 2020 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 10 Jun 2020 |
| 1 Nov 2019 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 9 Dec 2019 |
| 20 Sep 2019 | Josh GottheimerNJ05 | Sale | $1,001 - $15,000 | JT | 11 Oct 2019 |
| 14 Aug 2019 | Gilbert CisnerosCA39 | Purchase | $1,001 - $15,000 | Self | 11 Sep 2019 |
| 25 Mar 2019 | Nicholas Van TaylorTX03 | Sale | $15,001 - $50,000 | SP | 15 Apr 2019 |
| 7 Mar 2019 | Nicholas Van TaylorTX03 | Sale | $1,001 - $15,000 | SP | 15 Apr 2019 |
| 6 Feb 2019 | Nicholas Van TaylorTX03 | Sale | $1,001 - $15,000 | SP | 14 Mar 2019 |
| 22 Jan 2019 | Nicholas Van TaylorTX03 | Sale | $1,001 - $15,000 | SP | 15 Feb 2019 |
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
| 30 Sep 2026 | 2.2M | -14.89% | 2.49 |
| 15 Sep 2026 | 2.5M | -1% | 4.42 |
| 31 Aug 2026 | 2.6M | +6.51% | 3.85 |
| 14 Aug 2026 | 2.4M | -29.23% | 3.15 |
| 31 Jul 2026 | 3.4M | -3.29% | 3.94 |
| 15 Jul 2026 | 3.5M | +0.19% | 4.72 |
| 30 Jun 2026 | 3.5M | +5.75% | 2.91 |
| 15 Jun 2026 | 3.3M | +10.07% | 3.41 |
| 29 May 2026 | 3.0M | +7.95% | 1.96 |
| 15 May 2026 | 2.8M | -14.97% | 3.64 |
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
1,513
quarter to 30 Jun 2026
Added or new
566
since 31 Mar 2026
Trimmed
536
in the quarter
Largest holder
BlackRock, Inc.
$5.7B
| BlackRock, Inc. | $5.7B | 9.1M | +165.8K | Added | 0.09% | Filing ↗ |
| Vanguard Capital Management LLC | $4.1B | 6.6M | -25.2K | Trimmed | 0.09% | Filing ↗ |
| Dodge & Cox | $3.0B | 4.9M | +412.9K | Added | 1.59% | Filing ↗ |
| State Street Corp. | $3.0B | 4.8M | +170.2K | Added | 0.09% | Filing ↗ |
| Invesco Ltd. | $2.5B | 3.9M | +35.6K | Added | 0.19% | Filing ↗ |
| JPMorgan Chase & Co. | $2.4B | 3.8M | -537.6K | Trimmed | 0.14% | Filing ↗ |
| Vanguard Portfolio Management LLC | $2.0B | 3.2M | +1.5M | Added | 0.09% | Filing ↗ |
| Franklin Resources Inc. | $1.7B | 2.8M | +49.8K | Added | 0.38% | Filing ↗ |
| Geode Capital Management, LLC | $1.6B | 2.6M | +18.1K | Added | 0.09% | Filing ↗ |
| Nuveen, LLC | $1.3B | 2.0M | -45.1K | Trimmed | 0.30% | Filing ↗ |
| Loomis Sayles & Co. L P | $1.2B | 1.9M | -53.1K | Trimmed | 1.45% | Filing ↗ |
| Price T Rowe Associates Inc. | $953.8M | 1.5M | -647.8K | Trimmed | 0.10% | Filing ↗ |
| Morgan Stanley | $871.5M | 1.4M | +78.4K | Added | 0.05% | Filing ↗ |
| Bank of America Corp. | $805.0M | 1.3M | +101.5K | Added | 0.05% | Filing ↗ |
| Wellington Management Group LLP | $792.0M | 1.3M | -567.4K | Trimmed | 0.14% | Filing ↗ |
| Norges Bank | $731.3M | 1.2M | – | Held | 0.07% | Filing ↗ |
| Goldman Sachs Group Inc. | $725.3M | 1.2M | -137.4K | Trimmed | 0.08% | Filing ↗ |
| AQR Capital Management LLC | $702.2M | 1.1M | -104.9K | Trimmed | 0.24% | Filing ↗ |
| Amundi | $632.0M | 1.0M | +3.7K | Added | 0.15% | Filing ↗ |
| Northern Trust Corp. | $571.5M | 916.5K | -25.5K | Trimmed | 0.07% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $527.7M | 846.3K | +41.8K | Added | 0.07% | Filing ↗ |
| FMR LLC | $518.8M | 832.0K | -686.2K | Trimmed | 0.02% | Filing ↗ |
| Capital World Investors | $508.1M | 814.9K | -604.1K | Trimmed | 0.06% | Filing ↗ |
| Legal & General Group Plc | $473.9M | 760.0K | +27.9K | Added | 0.10% | Filing ↗ |
| Bank of New York Mellon Corp | $473.0M | 758.5K | -6.9K | Trimmed | 0.08% | Filing ↗ |
| UBS AM, a distinct business unit of UBS Asset Management Americas LLC | $446.8M | 716.6K | -7.1K | Trimmed | 0.08% | Filing ↗ |
| Two Sigma Investments, LP | $409.1M | 656.1K | -156.1K | Trimmed | 0.32% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $351.5M | 563.7K | -6.2K | Trimmed | 0.08% | Filing ↗ |
| Dimensional Fund Advisors LP | $349.0M | 559.7K | +46.6K | Added | 0.06% | Filing ↗ |
| First Trust Advisors LP | $341.2M | 547.1K | +200.3K | Added | 0.20% | Filing ↗ |
| Deutsche Bank AG | $323.2M | 518.4K | -107.0K | Trimmed | 0.09% | Filing ↗ |
| Assenagon Asset Management S.A. | $305.4M | 489.9K | – | Held | 0.20% | Filing ↗ |
| Robeco Institutional Asset Management B.V. | $287.2M | 460.6K | +111.8K | Added | 0.35% | Filing ↗ |
| Man Group plc | $272.5M | 437.0K | +121.7K | Added | 0.51% | Filing ↗ |
| SG Americas Securities, LLC | $266.7M | 427.7K | +269.4K | Added | 0.15% | Filing ↗ |
| Neuberger Berman Group LLC | $263.1M | 422.0K | -5.2K | Trimmed | 0.18% | Filing ↗ |
| BNP Paribas Financial Markets | $249.3M | 399.8K | -48.5K | Trimmed | 0.13% | Filing ↗ |
| Arrowstreet Capital, Limited Partnership | $245.5M | 393.7K | +222.1K | Added | 0.11% | Filing ↗ |
| HSBC Holdings PLC | $238.5M | 382.0K | +58.7K | Added | 0.12% | Filing ↗ |
| Allianz Asset Management GmbH | $237.3M | 380.6K | +79.4K | Added | 0.22% | Filing ↗ |
| National Pension Service | $236.8M | 379.8K | +8.3K | Added | 0.15% | Filing ↗ |
| Pacer Advisors, Inc. | $230.4M | 369.5K | +10.8K | Added | 0.60% | Filing ↗ |
| Nordea Investment Management AB | $227.4M | 363.5K | +269.2K | Added | 0.18% | Filing ↗ |
| AllianceBernstein L.P. | $225.9M | 292.3K | -134.6K | Trimmed | 0.07% | Filing ↗ |
| Worldquant Millennium Advisors LLC | $220.7M | 354.0K | +253.3K | Added | 0.76% | Filing ↗ |
| Citigroup Inc. | $216.1M | 346.6K | +161.9K | Added | 0.10% | Filing ↗ |
| BNP Paribas Asset Management Holding S.A. | $206.7M | 331.6K | +58.4K | Added | 0.21% | Filing ↗ |
| UBS Group AG | $186.0M | 298.2K | -1.7K | Trimmed | 0.03% | Filing ↗ |
| Swiss National Bank | $182.7M | 293.0K | -10.1K | Trimmed | 0.10% | Filing ↗ |
| Sumitomo Mitsui Trust Group, Inc. | $176.0M | 282.2K | +8.5K | Added | 0.10% | Filing ↗ |
Executive pay and performance
What the chief executive and the other named officers were paid, as reported and as actually paid, next to the shareholder return and net income, from each proxy's pay-versus-performance table.
| Fiscal year | CEO pay, as reported | CEO pay, actually paid | Other officers, as reported (average) | Other officers, actually paid (average) | Shareholder return, $100 | Peer return, $100 | Net income | stock price | Proxy |
|---|---|---|---|---|---|---|---|---|---|
| FY ending 31 Dec 2025 | $7.3M | $39.0M | $7.7M | $14.7M | $160 | $201 | $4.50B | 772 | DEF 14A 24 Apr 2026 |
| FY ending 31 Dec 2024 | $6.8M | $-37.7M | $6.1M | $-9.2M | $147 | $156 | $4.41B | 712 | DEF 14A 24 Apr 2026 |
| FY ending 31 Dec 2023 | $8.2M | $141.1M | $6.7M | $46.9M | $182 | $144 | $3.95B | 878 | DEF 14A 24 Apr 2026 |
| FY ending 31 Dec 2022 | $7.0M | $98.8M | $8.1M | $32.2M | $149 | $139 | $4.34B | 721 | DEF 14A 24 Apr 2026 |
| FY ending 31 Dec 2021 | $6.5M | $123.7M | $7.5M | $40.2M | $131 | $124 | $8.08B | 632 | DEF 14A 24 Apr 2026 |
| FY ending 31 Dec 2020 | $135.4M | $153.0M | $40.1M | $48.6M | $129 | $111 | $3.51B | 483 | DEF 14A 29 Apr 2025 |
Each year from the newest proxy that reports it. Pay actually paid follows the SEC's definition and can be below zero when share awards fall in value. n the proxy's net income differs from the 10-K or was tagged without its scale: hover for which.
Shareholder votes
The vote count on every proposal at each meeting, from the company's 8-K.
| Proposal | For | Against or withheld | Abstain | Broker non-votes | For, % of for and against | Result |
|---|---|---|---|---|---|---|
| Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: | ||||||
| Joseph L. Goldstein, M.D. | 72,398,297 | 30,904,254 | 170,603 | 5,543,411 | 70.1% | – |
| Christine A. Poon | 79,409,070 | 24,004,880 | 59,204 | 5,543,411 | 76.8% | – |
| David P. Schenkein, M.D. | 99,241,219 | 4,180,107 | 51,828 | 5,543,411 | 96.0% | – |
| Craig B. Thompson, M.D. | 81,933,651 | 21,378,567 | 160,936 | 5,543,411 | 79.3% | – |
| Huda Y. Zoghbi, M.D. | 100,665,234 | 2,698,397 | 109,523 | 5,543,411 | 97.4% | – |
| Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the follo | ||||||
| All shares voting | 102,503,788 | 6,443,958 | 68,819 | – | 94.1% | – |
| Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes: | ||||||
| All shares voting | 96,469,374 | 6,898,268 | 105,512 | 5,543,411 | 93.3% | – |
Counts as the company reports them in its 8-K. A result shows when the filing states one. Meetings since 2023.
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
| FY2025 | – | $370.3M | $3.4B |
| FY2024 | – | $0 | $2.6B |
| FY2023 | – | $0 | $2.2B |
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc.this company | $85.4B | $15.5B | 9.3% | 24.7% | 27.9% | 13.7% | 19.9× | 19.4× |
| Eli Lilly & Co. | $1.20T | $79.7B | 49.6% | – | 33.5% | 78.8% | 42.7× | – |
| Johnson & Johnson | $635.2B | $99.3B | 7.8% | – | 16.2% | 19.7% | 40.0× | – |
| AbbVie Inc. | $504.8B | $64.4B | 10.4% | 26.2% | 9.8% | – | 80.7× | 23.0× |
| Merck & Co., Inc. | $358.4B | $66.6B | 4.6% | – | 4.8% | 7.6% | 116.2× | – |
| Novartis AG | $288.3B | $54.5B | 8.4% | – | – | 30.3% | 21.1× | – |
| AstraZeneca PLC | $266.0B | $58.7B | 8.6% | 23.4% | 17.4% | 21.0% | 26.2× | – |
| Abbott Laboratories | $179.4B | $46.6B | 8.1% | 15.8% | 11.6% | 10.6% | 33.6× | 19.2× |
| Novo Nordisk A/S | $174.3B | $46.8B | 6.4% | 41.3% | 33.1% | 52.8% | 11.3× | – |
| Pfizer Inc. | $171.1B | $63.7B | -0.2% | – | 6.8% | 5.1% | 39.5× | – |
| Vertex Pharmaceuticals Inc. | $132.7B | $12.6B | 10.2% | 38.0% | 35.0% | 21.8% | 30.5× | 25.3× |
What the company does
Regeneron is a fully integrated biotechnology company that invents, develops, manufactures and commercialises medicines for people with serious diseases. Its products and candidates address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Its stated strategy is to keep a foundation in scientific research and drug development on its own proprietary technologies and build clinical development, manufacturing and commercial capability on top of it.
At the end of 2025 it had 15,410 full-time employees: 11,961 in the United States, 2,149 in Ireland and 1,300 elsewhere, mainly the United Kingdom, Japan and Germany. Of those, 2,591 worked in research and preclinical development, 2,274 in global clinical development and regulatory affairs, and 6,717 in industrial operations and product supply. More than 1,800 of the full-time employees hold a PhD or an MD.
The eye business
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence